Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


08.01.2024

1 Am J Hum Genet
2 Anticancer Res
2 BMC Cancer
1 BMC Urol
1 Cancer
1 Cancer Res
1 Curr Treat Options Oncol
2 Eur Radiol
1 Hum Pathol
1 Int J Cancer
3 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 Invest Radiol
5 J Nucl Med
2 N Engl J Med
1 Nat Rev Urol
3 Prostate
4 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hum Genet

  1. LI X, Sham PC, Zhang YD
    A Bayesian fine-mapping model using a continuous global-local shrinkage prior with applications in prostate cancer analysis.
    Am J Hum Genet. 2023 Dec 27:S0002-9297(23)00439.
    PubMed         Abstract available


    Anticancer Res

  2. OKA D, Sekine Y, Tsuji Y, Nakayama H, et al
    Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression.
    Anticancer Res. 2024;44:93-98.
    PubMed         Abstract available

  3. REINIKAINEN P, Lehtinen I, Luukkaala T, Kellokumpu-Lehtinen PL, et al
    Safer and More Convenient Modern Curative Radiotherapy for Patients With Early Prostate Cancer.
    Anticancer Res. 2024;44:139-150.
    PubMed         Abstract available


    BMC Cancer

  4. ZHAO S, Miao M, Wang Q, Zhao H, et al
    The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
    BMC Cancer. 2024;24:30.
    PubMed         Abstract available

  5. ZHOU X, Chai K, Zhu H, Luo C, et al
    The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target.
    BMC Cancer. 2024;24:8.
    PubMed         Abstract available


    BMC Urol

  6. BORG MA, O'Callaghan ME, Moretti KL, Vincent AD, et al
    External validation of predictive models of sexual, urinary, bowel and hormonal function after surgery in prostate cancer subjects.
    BMC Urol. 2024;24:2.
    PubMed         Abstract available


    Cancer

  7. MCKAY RR, Xie W, Yang X, Acosta A, et al
    Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized ph
    Cancer. 2024 Jan 1. doi: 10.1002/cncr.35170.
    PubMed         Abstract available


    Cancer Res

  8. ZHAO J, Xu N, Zhu S, Nie L, et al
    Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
    Cancer Res. 2024;84:154-167.
    PubMed         Abstract available


    Curr Treat Options Oncol

  9. KAMRAN SC, Vapiwala N
    Approach to Patients with High-Risk Localized Prostate Cancer: Radiation Oncology Perspective.
    Curr Treat Options Oncol. 2024 Jan 3. doi: 10.1007/s11864-023-01163.
    PubMed         Abstract available


    Eur Radiol

  10. MAZZETTI S, Defeudis A, Nicoletti G, Chiorino G, et al
    Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.
    Eur Radiol. 2024 Jan 4. doi: 10.1007/s00330-023-10542.
    PubMed         Abstract available

  11. PANEBIANCO V
    Prostate cancer imaging for primary detection: PSMA-PET/CT vs MRI. All that glitters is not gold.
    Eur Radiol. 2024 Jan 2. doi: 10.1007/s00330-023-10547.
    PubMed        


    Hum Pathol

  12. DING Y, Bu P, Assylbekova B, Ruder S, et al
    Quantification of collagen content and stromal cellularity within reactive stroma is predictive of prostate cancer biochemical recurrence and specific death.
    Hum Pathol. 2023 Dec 28:S0046-8177(23)00258.
    PubMed         Abstract available


    Int J Cancer

  13. LEHTO TK, Pylvalainen J, Sandeman K, Kenttamies A, et al
    Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
    Int J Cancer. 2024;154:926-939.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  14. ACHARD V, Zilli T, Lamanna G, Jorcano S, et al
    Urethra-sparing prostate cancer stereotactic body radiotherapy: sexual function and radiation dose to the penile bulb, the crura, and the internal pudendal arteries from a randomized phase 2 trial.
    Int J Radiat Oncol Biol Phys. 2023 Dec 29:S0360-3016(23)08307.
    PubMed         Abstract available

  15. NEYLON J, Ma TM, Savjani R, Low DA, et al
    Quantifying Intrafraction Motion and the Impact of Gating for MRI-guided Stereotactic Radiotherapy for Prostate Cancer: Analysis of the MRI arm from the MIRAGE Phase III Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2023 Dec 29:S0360-3016(23)08309.
    PubMed         Abstract available

  16. CHOUDHURY M, Thomas SS, Cain A, Palvai S, et al
    Timing of High-Dose Rate Brachytherapy with External Beam Radiotherapy in intermediate and high-risk localised Prostate Cancer (THEPCA): a randomised trial.
    Int J Radiat Oncol Biol Phys. 2023 Dec 30:S0360-3016(23)08137.
    PubMed         Abstract available


    Int J Urol

  17. DE VELASCO MA, Kura Y, Fujita K, Uemura H, et al
    Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    Int J Urol. 2024 Jan 2. doi: 10.1111/iju.15378.
    PubMed         Abstract available

  18. NAITO Y, Kato M, Nagayama J, Sano Y, et al
    Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
    Int J Urol. 2024;31:7-16.
    PubMed         Abstract available


    Invest Radiol

  19. TENBERGEN CJA, Fortuin AS, van Asten JJA, Veltien A, et al
    The Potential of Iron Oxide Nanoparticle-Enhanced MRI at 7 T Compared With 3 T for Detecting Small Suspicious Lymph Nodes in Patients With Prostate Cancer.
    Invest Radiol. 2023 Dec 29. doi: 10.1097/RLI.0000000000001056.
    PubMed         Abstract available


    J Nucl Med

  20. GRAVES SA
    Radiation Safety Considerations of Household Waste Disposal After Release of Patients Who Have Received [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2023;64:1567-1569.
    PubMed         Abstract available

  21. STEINHELFER L, Lunger L, Cala L, Pfob CH, et al
    Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy.
    J Nucl Med. 2024;65:79-84.
    PubMed         Abstract available

  22. RAVI KUMAR AS, Hofman MS
    Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.
    J Nucl Med. 2024;65:85-86.
    PubMed        

  23. DIERKS A, Gable A, Rinscheid A, Wienand G, et al
    First Safety and Efficacy Data with the Radiohybrid (177)Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer.
    J Nucl Med. 2023 Dec 21:jnumed.123.266741. doi: 10.2967/jnumed.123.266741.
    PubMed         Abstract available

  24. SCHILHAM MGM, Somford DM, Kusters-Vandevelde HVN, Hermsen R, et al
    Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.
    J Nucl Med. 2024 Jan 4:jnumed.123.266495. doi: 10.2967/jnumed.123.266495.
    PubMed         Abstract available


    N Engl J Med

  25. SHORE ND, Tarazi J, Freedland SJ
    Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
    N Engl J Med. 2024;390:90-91.
    PubMed        

  26. POLLAK M
    Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2024;390:90.
    PubMed        


    Nat Rev Urol

  27. PEKALA KR, Shill DK, Austria M, Langford AT, et al
    Shared decision-making before prostate cancer screening decisions.
    Nat Rev Urol. 2024 Jan 2. doi: 10.1038/s41585-023-00840.
    PubMed         Abstract available


    Prostate

  28. DE KOUCHKOVSKY I, Chan E, Schloss C, Poehlein C, et al
    Diagnosis and management of neuroendocrine prostate cancer.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24664.
    PubMed         Abstract available

  29. ZHANG C, Tu X, Dai J, Zhang Z, et al
    Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24669.
    PubMed         Abstract available

  30. OZAWA Y, Nohara S, Nakamura K, Hattori S, et al
    Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24668.
    PubMed         Abstract available


    Urology

  31. GARCIA ROJO E, Garcia Gomez B, Sopena Sutil R, Vallejo Arzayus D, et al
    Comparison in Detection Rate of Clinically Significant Prostate Cancer Between Microultrasound-guided Prostate Biopsy (ExactVu) and Multiparametric Resonance Imaging-guided Prostate Biopsy (Koelis System).
    Urology. 2024;183:163-169.
    PubMed         Abstract available

  32. GUPTA N, Zebib L, Wittmann D, Nelson CJ, et al
    Unmet sexual health resource needs and preferences for interventions to address these needs among female partners of patients with prostate cancer.
    Urology. 2023 Dec 29:S0090-4295(23)01109-3. doi: 10.1016/j.urology.2023.
    PubMed         Abstract available

  33. DIRK K, Rourke K
    Health-Related Quality of Life in Patients with Urethral Stenosis after Radiation Treatment for Prostate Cancer.
    Urology. 2023 Dec 29:S0090-4295(23)01113-5. doi: 10.1016/j.urology.2023.
    PubMed         Abstract available

  34. NITHIPALAN V, Holler T, Schuler N, Shepard L, et al
    Evaluation of Mixed Reality Technologies for Remote Feedback and Guidance During Transrectal Ultrasound Biopsy Simulation: A Prospective, Randomized, Crossover Study.
    Urology. 2024;183:25-31.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.